Featured Research

from universities, journals, and other organizations

People at 'intermediate risk' of heart disease with elevated hsCRP benefit from statin therapy, study suggests

Date:
August 30, 2010
Source:
American Heart Association
Summary:
People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein, a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels. Data indicates that people with only a 5 percent to 20 percent risk of having heart disease in the next 10 years, but who have high levels of hsCRP could reduce the risk of heart attack and stroke by more than 40 percent.

People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein (hsCRP), a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels. Data indicates that people with only a 5 percent to 20 percent risk of having heart disease in the next ten years, but who have high levels of hsCRP could reduce the risk of heart attack and stroke by more than 40 percent.

Women and men with a 10-year cardiovascular disease risk of 5 percent or more and normal cholesterol levels but high levels of hsCRP, a protein associated with inflammation, could reduce their risk substantially with statin therapy, according to new research.

The study, published in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal, is a new analysis of data from the randomized, placebo-controlled, double blind Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). The study included men age 50 yrs or older and women age 60 yrs or older.

For patients with elevated high sensitivity C-reactive protein (hsCRP) -- a protein associated with systemic inflammation -- the study found that taking cholesterol-lowering statin drugs could:

  • reduce the relative risk of cardiovascular disease (CVD) by 45 percent for people estimated to have a 10-year CVD risk of 5 percent to 10 percent ; and
  • reduce the relative risk by 49 percent among those with an estimated 11 percent to 20 percent 10-year risk.

"These data demonstrate that women and men with elevated hsCRP who are otherwise at 5 percent to 20 percent 10-year risk had substantive risk reductions with statin therapy even though they are currently outside United States treatment guidelines," said Paul Ridker, M.D., lead study author and director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, Boston, Mass. Ridker is also principal investigator of JUPITER.

People with a 10-year risk of less than 5 percent did not have a statistically significant reduction in events with statins.

He said recent changes in Canadian prevention guidelines prompted a need to better define CVD risk. The new Canadian recommendations call for statin therapy for patients who have "intermediate risk" -- defined as 10 percent to 19 percent 10-year risk -- and elevated hsCRP, even if their cholesterol levels are in the normal range (i.e. LDL-cholesterol below 130 mg/dL).

"The new Canadian guidelines are a major step forward for prevention and incorporate hsCRP in a thoughtful manner" Ridker said. "However, intermediate risk was defined in the Canadian guidelines as 10 to 20 percent 10-year risk, yet we observed major benefits of statin therapy for those with risks of 5 to 10 percent as well." He added that many physicians incorrectly consider a 5 percent to 10 percent risk score to be "low-risk," especially in woman who tend to develop CVD at least a decade later than men, although heart and blood vessel disease remains the number one killer of women and men.

Risk is calculated with screening tools, such as the Framingham Risk Score, which predicts CVD risk based on traditional risk factors such as age, gender, smoking, blood pressure and cholesterol; or the Reynolds Risk Score which also considers hsCRP and parental history of premature heart disease.

The current study finds that although men and women in the 5 percent to 10 percent Framingham 10-year risk group get equal benefit from statin therapy, more women tend to be in the 5 percent to 10 percent risk group while men tend to be in the 11 to 20 percent group.

"The current U.S. recommendations label individuals with a greater than 20 percent 10-year Framingham risk as high risk and advise statin therapy for them. Statin treatment for individuals with Framingham risk under 20 percent has until now been less clear-cut."

These data also support the current position taken by the American Heart Association and the U.S. Centers for Disease Control that hsCRP testing is best used in people with intermediate risk to help doctors in their treatment decisions. Statins are known to reduce levels of both cholesterol and hsCRP. In addition, he said statin therapy is no substitute for a healthy diet, smoking cessation and exercise.

"This analysis of the JUPITER study provides important information indicating the groups of men and women who have high CRP and normal LDL-cholesterol that could benefit from statin treatment," said Pamela Ouyang, M.D, professor of medicine at Johns Hopkins University and an American Heart Association volunteer. "The statin used in the JUPITER study was rosuvastatin at a dose of 20 mg. The degree of lowering in risk that would be obtained using lower doses or less potent statin therapy is not known."

Co-authors are Jean G. MacFadyen, B.A.; Børge G. Nordestgaard, M.D.; Wolfgang Koenig, M.D.; John J.P. Kastelein, M.D.; Jacques Genest, M.D.; and Robert J Glynn, Sc.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. Paul M Ridker, Jean G. MacFadyen, Børge G. Nordestgaard, Wolfgang Koenig, John J.P. Kastelein, Jacques Genest, and Robert J. Glynn. Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk: Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvas. Circ Cardiovasc Qual Outcomes, Aug 24, 2010 DOI: 10.1161/CIRCOUTCOMES.110.938118

Cite This Page:

American Heart Association. "People at 'intermediate risk' of heart disease with elevated hsCRP benefit from statin therapy, study suggests." ScienceDaily. ScienceDaily, 30 August 2010. <www.sciencedaily.com/releases/2010/08/100824161503.htm>.
American Heart Association. (2010, August 30). People at 'intermediate risk' of heart disease with elevated hsCRP benefit from statin therapy, study suggests. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2010/08/100824161503.htm
American Heart Association. "People at 'intermediate risk' of heart disease with elevated hsCRP benefit from statin therapy, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/08/100824161503.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) — The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) — Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins